| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Alprenolol HCl (alfeprol, alpheprol) is a potent and non-selective beta blocker as well as 5-HT1A receptor antagonist, used in the treatment of angina pectoris. It is no longer marketed by AstraZeneca, but may still be available from other pharmaceutical companies or generically.
| ln Vivo |
In conscious, renally hypertensive dogs, oral apropralol hydrochloride (50 mg/kg) dramatically lowers blood pressure, with an average drop of 20 mm Hg and an increase in heart rate of 39 beats per minute (3 hours) [1]. In adult male Swiss Webster mice, alpronolol (ip, 5 mg/kg) hydrochloride does not decrease locomotor activity but does effectively block the anxiolytic effects of indomethacin and ixabepilone [2]. cats' heart rate dropped by 23 beats per minute, and at a dose of 1.0 mg/kg, cats' myocardial and hepatic blood flow decreased by an average of 17% and 15%, respectively. Aprapralol (IV, 0.5 or 1.0 mg/kg) decreased systolic blood pressure by an average of 10 mm Hg and diastolic blood pressure by an average of 10 mm Hg) hydrochloride.
|
|---|---|
| References |
[1]. Himori N, et al. Effects of beta-adrenoceptor blocking agents, pindolol, alprenolol and practolol on blood pressure and heart rate in conscious renal hypertensive dogs. Arch Int Pharmacodyn Ther. 1977 Jan;225(1):152-65.
[2]. Fernández-Guasti A, et al. Evidence for the involvement of the 5-HT1A receptor in the anxiolytic action of indorenate and ipsapirone. Psychopharmacology (Berl). 1990;101(3):354-8. [3]. Parratt JR, et al. Myocardial and haemodynamic effects of the beta-adrenoceptor blocking drug alprenolol (H56/28) in anaesthetized cats. Br J Pharmacol. 1969 Oct;37(2):357-66. |
| Molecular Formula |
C15H24CLNO2
|
|---|---|
| Molecular Weight |
285.8096
|
| CAS # |
13707-88-5
|
| Related CAS # |
Alprenolol;13655-52-2
|
| SMILES |
CC(C)NCC(COC1=CC=CC=C1CC=C)O
|
| InChi Key |
PAZJSJFMUHDSTF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H23NO2/c1-4-7-13-8-5-6-9-15(13)18-11-14(17)10-16-12(2)3/h4-6,8-9,12,14,16-17H,1,7,10-11H2,2-3H3
|
| Chemical Name |
1-(propan-2-ylamino)-3-(2-prop-2-enylphenoxy)propan-2-ol
|
| Synonyms |
Gubernal Regletin Yobir Apllobal Alfeprol Alpheprol
Yobir Alprenololum Alpheprol Aptin Aptin Duriles Aptin-Duriles
Aptina AptinDuriles Aptine
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~349.88 mM)
H2O : ~50 mg/mL (~174.94 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (7.28 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 11 mg/mL (38.49 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4988 mL | 17.4941 mL | 34.9883 mL | |
| 5 mM | 0.6998 mL | 3.4988 mL | 6.9977 mL | |
| 10 mM | 0.3499 mL | 1.7494 mL | 3.4988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA